HLA-C and cancer: Early studies of the MCA sarcoma model illustrated a high TMB, and in silico neoantigen prediction algorithms were able to identify neoantigenic peptides with strong MHC binding (relative to that of wild-type peptides), which resulted from amino acid sequence changes that were unique to the cancer.